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1. Introduction 
In 1990 the American College of Rheumatology (ACR) established criteria for the diagnosis 
of fibromyalgia (Wolfe et al., 1990), and more recently new criteria have been proposed 
(Wolfe et al., 2010, 2011). However, the absence of anatomic pathological lesions and of 
biohumoral abnormalities, demonstrated with classical instrumental methods, has led to 
considerable difficulties in diagnosis. 
Until now, many attempts have been made to search for biomarkers in fibromyalgia, but at 
present no specific markers have been found (Bazzichi et al., 2010). The problem lies in the 
presence of too many data, often controversial, rather than in a lack of data. 
We will discuss methods that are state of the art in searching for biomarkers in fibromyalgia. 
Furthermore, we will focus on the contribution that proteomics can give in the diagnosis of 
the disease on the basis of the study we carried out on human whole saliva of patients 
affected by fibromyalgia.  
2. Genetic markers 
The presence of fibromyalgia in family clusters and many studies support the idea that 
genetic factors may predispose to fibromyalgia in combination with environmental triggers 
such as trauma, infections or emotional stress. The principal gene polymorphisms supposed 
to be a risk factor for fibromyalgia are those implicated in mood disorders but results are 
often controversial. 
These candidate genes include the serotonin transporter (5-HTT), the serotonin 2A (5-HT2A) 
receptor, catechol-O-methyltransferase (COMT) and the dopamine receptor.  
Offenbaecher and colleagues (Offenbaecher et al., 1999) were the first to analyze the 
genotypes of the serotonin transporter promoter locus (5HTTLPR) in patients with 
fibromyalgia. They found that the S/S genotype of 5-HTT occurred more frequently in 
fibromyalgia patients than in healthy controls. This association is interesting considering 
that 5-HTT is involved in many conditions that are either risk factors for —or frequent 
concomitants to— fibromyalgia, such as anxiety, Bipolar Disorder, Psychosis, attention 
deficit hyperactivity disorder, and Major Depressive Disorder (Maletic & Raison, 2009). 
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Cohen and collaborators subsequently confirmed this association between fibromyalgia and 
5-HTTLPR polymorphism (Cohen et al., 2002).  
However, these data were not found in all studies. Recently, Lee and collaborators (Lee et 
al., 2010) conducted a meta-analysis, and from their results no association was found 
between 5-HTTLPR and fibromyalgia susceptibility. Potvin et al. found no evidence of a 
relationship between 5-HTTLPR and fibromyalgia-related psychiatric symptoms (Potvin et 
al., 2010). Thus, their results are inconsistent with previous reports from Offenbaecher and 
Cohen but in agreement with those of Gürsoy who concluded that neither 5-HTT nor its 
polymorphism is associated with fibromyalgia (Gürsoy, 2002). 
5-HT2A is also a candidate for involvement in fibromyalgia. Bondy et al., investigated the 
T102C polymorphism of the 5-HT2A receptor gene and found a significantly different 
genotype distribution in fibromyalgia patients who had a decrease in T/T and an increase in 
both T/C and C/C genotypes as compared with the control population (Bondy et al., 1999). 
In contrast, the pain score was significantly higher for patients with the T/T genotype. It 
was suggested that the T102 allele might be involved in the complex circuits of nociception. 
Lee and collaborators using meta-analysis, provided evidence of an association of the 5-
HT2A receptor with fibromyalgia susceptibility (Lee et al., 2010). On the contrary, Gürsoy, 
after studying T102C polymorphism in Turkish patients, concluded that it is not associated 
with the etiology of fibromyalgia (Gürsoy et al., 2001). Similar results were described by 
Matsuda et al. in the Brazilian population (Matsuda et al., 2010), and by Tander in a 
population of eighty patients (Tander et al., 2008). 
Another area of investigation is the COMT gene. This gene has long been implicated to be 
involved in the pathogenesis of neuropsychiatric disorders, schizophrenia, bipolar affective 
disorder, migraine, and Parkinson’s disease. In 2003, Zubieta et al. showed a positive 
relationship between the COMT gene polymorphism and the experience of pain (Zubieta et 
al., 2003). Their study focused on the val158met polymorphism, a single nucleotide 
polymorphism in codon 158 of the COMT gene, which substitutes valine for methionine and 
resulting in reduced enzyme activity. Individual homozygous for the met158 allele of this 
polymorphism showed a diminished mu-opioid system response to pain, compared with 
heterozygotes. Opposite effects on pain and negative effects have been found in val158 
homozygotes. The conclusion was that COMT val158met polymorphism influences the 
human experience of pain and may underlie interindividual differences in the adaptation 
and responses to pain and other stressful stimuli (Zubieta et al., 2003). On the other hand, an 
extensive study on the association between this polymorphism and chronic widespread pain 
concluded that COMT pain sensitivity haplotypes do not play a role in disease 
susceptibility. The authors proposed that the genetics of chronic widespread pain may differ 
from that of other pain syndromes (Nicholl et al., 2010).  
Cohen et al. observed an association between fibromyalgia and this polymorphism. 
Moreover, they found that unaffected relatives of fibromyalgia patients had a reduced 
percentage of the COMT met allele (Cohen et al., 2009). They suggested that this reduced 
frequency acts as a 'protective' allele in this group and prevents the development of clinical 
fibromyalgia (Cohen et al., 2009).  
Gürsoy and collaborators assessed the significance of COMT polymorphism in 
fibromyalgia. There were three polymorphisms of the COMT gene: LL, LH, and HH. The 
analysis of COMT polymorphism was performed using a polymerase chain reaction. The LL 
and LH genotypes together were more highly represented in patients than in controls. In 
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addition, HH genotypes in patients were significantly lower than in the control group 
(Gürsoy et al., 2003). It was concluded that COMT polymorphism is of potential 
pharmacological importance concerning individual differences in the metabolism of 
catechol drugs. In addition, it may also be involved in the pathogenesis and treatment of 
fibromyalgia through adrenergic mechanisms as well as in the genetic predisposition to 
fibromyalgia (Gürsoy et al., 2003). Matsuda et al. confirmed these results in the Brazilian 
population (Matsuda et al., 2010) showing that the LL genotype was more frequently found 
among fibromyalgia patients.  
On the other hand, Tander and subsequently Lee didn’t find any associations between the 
COMT gene and fibromyalgia (Lee et al., 2010; Tander et al., 2008). 
Finally, some studies have established a connection between fibromyalgia and the 
dopaminergic system.  
Dopaminergic neurotransmission was found to be altered in fibromyalgia patients by Malt 
and colleagues. They suggested an increased sensitivity or density of dopamine D2 receptors 
in fibromyalgia patients (Malt et al., 2003). Buskila and collaborators demonstrated an 
association between fibromyalgia and the 7-repeat allele in exon III of the D4 receptor gene, 
specifically that the frequency of this polymorphism was significantly lower in people with 
fibromyalgia (Buskila et al., 2004). More recently, Treister et al. found an association 
between the dopamine transporter gene (DAT-1) polymorphism and cold pain tolerance. 
Their results, together with the known function of the investigated candidate gene 
polymorphisms, suggest that low dopaminergic activity can be associated with high pain 
sensitivity (Treister et al., 2009). However, Ablin and co-workers, investigating an 
association between fibromyalgia and DAT1, found no significant association between 
fibromyalgia and the genetic marker (Ablin et al., 2009).  
All these findings are summarised in Table 1. 
 
Reference Year Studied gene and findings in fibromyalgia 
Offenbaecher  
et al. 
1999 5-HTT The S/S genotype of 5-HTT occurred more 
frequently in fibromyalgia patients than in 
healthy controls. 
Cohen et al. 2002  Association between fibromyalgia and 
serotonin transporter promoter region  
(5-HTTLPR) polymorphism. 
Gürsoy  2002  no association 
Lee et al.  2010  no association 
Potvin et al. 2010  no association 
Bondy et al.  1999 5-HT2A They investigated the T102C polymorphism 
finding a significantly different genotype 
distribution in fibromyalgia patients with a 
decrease in T/T and an increase in both T/C 
and C/C genotypes as compared with the 
control population. 
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Lee et al.  2010  They found an association of the 5-HT2A 
receptor with fibromyalgia susceptibility. 
Gürsoy et al. 2001  no association 
Tander et al. 2008  no association 
Matsuda et al. 2010  no association 
Gürsoy et al. 2003 COMT Authors assessed the significance of COMT 
polymorphism in fibromyalgia. The LL and 
LH genotypes together were more highly 
represented in patients than controls. In 
addition, HH genotypes in patients were 
significantly lower than in the control group. 
Zubieta et al. 2003  COMT val158met polymorphism influences 
the experience of pain. 
Cohen et al. 2009  They found an association between 
fibromyalgia and the val158met 
polymorphism of COMT gene. 
Matsuda et al. 2010  The L/L genotype was more frequent among 
fibromyalgia patients. 
Tander et al. 2008  no association 
Lee et al. 2010  no association 
Nicholl et al. 2010  No evidence of association between the COMT 
pain sensitivity haplotypes and chronic 
widespread pain. 
Malt et al. 2003 D2 receptor The authors suggested an increased sensitivity 
or density of dopamine D2 receptors in 
fibromyalgia patients 
Buskila et al. 2004 D4 receptor They have demonstrated an association 
between fibromyalgia and the 7 repeat allele in 
exon III of the D4 receptor gene. Specifically, 
the frequency of this polymorphism was 
significantly lower in patients with 
fibromyalgia. 
Treister et al. 2009 DAT1 A significant association was found between 
the quantitative measure of cold tolerance and 
DAT-1 polymorphism. 
Ablin et al. 2009  no association 
 
Table 1. Genetics in fibromyalgia. 
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In conclusion, all these genetic studies support a role for the polymorphism of genes of the 
serotoninergic, catecholaminergic and dopaminergic systems in the etiopathogenesis of 
fibromyalgia.  
These polymorphism are often associated with psychiatric disorders, thereby they could be 
related to psychiatric comorbidities rather than to sole fibromyalgia. Furthermore, genetic 
results are often controversial, and no specific candidate gene has been closely connected 
with fibromyalgia.  
3. Serologic markers 
There is a great interest in using a simple blood test to diagnose fibromyalgia. Thus, many 
attempts have been carried out in order to identify specific serologic markers. These results, 
as well as those of genetic studies, are often conflicting and, at present, no clinical test has 
been validated yet.  
3.1 Autoantibodies 
Autoimmunity has a central role in pathogenesis of many rheumatic diseases while 
fibromyalgia is generally considered to be a non-autoimmune disease. Nevertheless, a broad 
spectrum of autoantibodies has been widely investigated in the sera from patients. The 
studies have often generated controversial data, and the proposed antibodies don’t have 
diagnostic relevance yet.  
The association between the antipolymer antibody (APA) and fibromyalgia was evaluated 
because APAs were found in the sera of women with silicone breast implants presenting 
fibromyalgia-like symptoms (Wolfe, 1999). In addition, Wilson et al. found a higher 
prevalence of APAs (67%) in fibromyalgia patients in the USA population (Wilson et al., 
1999). Furthermore, a Danish study showed that fibromyalgia patients tended to have 
slightly higher APA levels than controls when adjusted for symptom severity (Jensen et al., 
2004). However, these results were not confirmed in the Italian population by Bazzichi and 
colleagues (Bazzichi et al., 2007). Instead, they found a lower percentage of APA 
seropositivity (23%) in fibromyalgia patients. A correlation between the APA and pain and 
fatigue severity in fibromyalgia was also proposed by Sarzi-Puttini et al. because the APA 
test did not distinguish this group from the controls, but instead a positive APA test 
prevalence increased with less severe pain or fatigue (Sarzi-Puttini et al., 2008). A more 
recent study evaluated the APA concentration in the serum of patients with fibromyalgia, 
patients with tension-type headache, and healthy controls. APAs were detected in only 
17.6% of fibromyalgia patients confirming the lack of diagnostic relevance of the APA 
(Iannuccelli et al., 2010). 
Two other autoantibodies, the anti-68/48 kDa and the anti-45 kDa, have been described as 
possible markers for certain clinical subsets of primary fibromyalgia and chronic fatigue 
syndrome, and for secondary fibromyalgia/psychiatric disorders, respectively (Nishikai et 
al., 2001).  
Antiserotonin, antiganglioside and antiphospholipid antibodies have been shown to be 
higher in fibromyalgia patients as well as in those with chronic fatigue syndrome, 
supporting the concept that fibromyalgia and chronic fatigue syndrome may belong to the 
same clinical entity and may manifest themselves as 'psycho-neuro-endocrinological 
autoimmune diseases' (Klein & Berg, 1995). A different group, evaluating the prevalence 
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and potential diagnostic relevance of antiserotonin, antithromboplastin and antiganglioside 
in patients with fibromyalgia, confirmed an elevated prevalence of antibodies against 
serotonin and thromboplastin, but they concluded that the measurement of these antibodies 
had no diagnostic relevance (Werle et al., 2001). 
Another important research field is thyroid autoimmunity. Bazzichi and collaborators found 
that autoimmune thyroiditis is present in an elevated percentage of fibromyalgia patients. In 
particular, 41% of these patients had at least one thyroid antibody, a percentage that was 
twice the value of the control group’s (Bazzichi et al., 2007). More recently, they confirmed 
this significant association between thyroid autoimmunity and fibromyalgia (Bazzichi et al., 
2010). Pamuk & Cakir also found a higher frequency of thyroid autoimmunity in 
fibromyalgia patients than in the control group, while the frequency was similar between 
fibromyalgia patients and the rheumatoid arthritis group (Pamuk & Cakir, 2007). 
Essentially, the association between rheumatic and thyroid disorders have long been 
known, the most common being the associations with rheumatoid arthritis, Sjögren’s 
syndrome, and systemic lupus erythematosus. 
Therefore, at present, the proposed antibodies have not been validated yet as being strong, 
useful diagnostic biomarkers for fibromyalgia and further studies are necessary to reach a 
research end point. 
3.2 Neuropeptides 
Neuropeptide Y is a neurotransmitter released mainly by sympathetic neurons in the 
autonomic nervous system, and it has a complex role in mediating analgesia and 
hyperalgesia. Thus, Neuropeptide Y has been shown, to both reduce and cause pain. 
Crofford and colleagues were the first to measure plasma Neuropeptide Y levels in 
fibromyalgia patients and they found that it was significantly lower in fibromyalgia patients 
than in normal subjects (Crofford et al., 1994). These results are inconsistent with subsequent 
findings from Anderberg who found significantly elevated plasma Neuropeptide Y levels in 
fibromyalgia patients compared with the healthy subjects (Anderberg et al, 1999). 
Furthermore, serum Neuropeptide Y levels have been shown to be significantly higher in 
fibromyalgia subjects, compared with healthy controls, by two different groups (Di Franco 
et al., 2009; Iannuccelli et al., 2010). 
Substance P is another neuropeptide extensively studied in fibromyalgia patients. Substance 
P is released in the cerebral spinal fluid when axons are stimulated. An increase in substance 
P levels in the cerebral spinal fluid can be related to an increase of pain neurotransmitters in 
the spinal cord. Two studies from two different groups have demonstrated significantly 
elevated substance P levels in cerebral spinal fluid of fibromyalgia patients (Russell et al., 
1994; Vaerøy et al., 1988) but levels of substance P determined in cerebral spinal fluid of 
patients with chronic fatigue syndrome were within normal range (Evengard et al., 1998). It 
was proposed that substance P in mice produces disturbances in sleep (Andersen et al., 
2006). Subsequently, it is likely that the high levels of substance P found in fibromyalgia 
patients may be one of the causes of sleep dysfunction. 
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family, which 
also includes the nerve growth factor. BDNF has a wide range of biological activities and is 
produced by different immune and structural cells (Iughetti et al., 2011). BDNF seems to 
have a role in Major Depressive Disorder, schizophrenia, and eating disorders such as 
bulimia and anorexia nervosa, Parkinson’s and Alzheimer’s diseases, and epileptic and 
psychogenic nonepileptic seizures (Iughetti et al., 2011). In addition, BDNF is a mediator of 
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pain in the peripheral nerve system, and some findings have also suggested an involvement 
of BDNF in pain syndrome (Laske et al., 2006). On the basis of this evidence, Laske and 
collaborators were the first to evaluate BDNF serum concentrations in fibromyalgia patients, 
and they found that levels significantly increased compared with healthy controls (Laske et 
al., 2006). Two different groups found significantly higher levels of BDNF in plasma and in 
the cerebral spinal fluid of fibromyalgia patients than in controls, indicating an involvement 
of BDNF in the pathophysiology of fibromyalgia (Haas et al., 2010; Sarchielli et al., 2007). 
The excitatory neurotransmitter glutamate is known to function in pain neuropathways, and it 
is suspected to play a role in the pathophysiology of fibromyalgia. This hypothesis is 
supported by different studies. Harris and collaborators found a correlation between changing 
levels of insular glutamate and changes in pain in patients with fibromyalgia using proton 
magnetic resonance spectroscopy and functional magnetic resonance imaging (Harris et al., 
2008). Subsequently, they extended these findings by investigating the relationship between 
insular glutamate and combined glutamate/glutamine in individuals with fibromyalgia  
and pain free controls (Harris et al., 2009). They concluded that enhanced glutamatergic 
neurotransmission within the posterior insula is a potential pathologic factor in fibromyalgia. 
In a pilot study, Fayed and colleagues compared three different magnetic resonance imaging 
examination methods for the diagnosis of fibromyalgia: magnetic resonance spectroscopy, 
diffusion-weighted imaging, and diffusion-tensor imaging. One of the principal findings was 
the increase in the combined glutamate+glutamine levels, and glutamate+glutamine/creatine 
ratio, in the posterior gyrus in patients with fibromyalgia compared with controls (Fayed et al., 
2010). Another group used magnetic resonance spectroscopy techniques to study brain 
metabolites in the amygdala, thalami, and prefrontal cortex of these women. Patients with 
fibromyalgia showed higher levels of glutamate compounds in the right amygdala than did 
healthy controls, and pain was related to increased glutamate levels in the left thalamus 
(Valdés et al., 2010). These findings have implications for future therapies directed against 
glutamate receptors, but further studies are desirable to confirm whether these findings are 
observed in other functional pain syndromes. 
3.3 Inflammation 
Since fibromyalgia is characterised by widespread pain, and the origin of pain is inflammation, 
many studies have focused on the inflammatory hypothesis for fibromyalgia, although 
fibromyalgia is generally regarded as a non-inflammatory disease. Special attention has been 
paid on circulating pro-inflammatory cytokines as possible markers in fibromyalgia patients.  
A connection between the pathogenesis of fibromyalgia and cytokines was suspected when 
in 1988, after being treated with IL-2 or IFN-ǂ, patients with malignant melanoma, renal cell 
carcinoma, and hairy cell leukaemia showed fibromyalgia-like symptoms such as myalgias, 
arthralgias, cognitive impairment, and painful tender points (Wallace et al., 1988, as cited in 
Di Franco et al., 2010). 
Therefore, cytokines have been suggested to be involved in the fibromyalgia syndrome, but 
results often appear to be controversial, especially because increases, reductions, and no 
significant changes have been reported. Levels of IL-10, an anti-inflammatory cytokine, were 
studied by four different groups with different findings. Wallace and Amel Kashipaz didn’t 
find alterations in IL-10 levels, while Bazzichi and co-workers found an increase in plasma 
levels, and Uçeyler found a reduction (Amel Kashipaz et al., 2003; Bazzichi et al., 2007;  
Uçeyler et al., 2006; Wallace et al., 2001). 
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IL-8, a pro-inflammatory cytokine, has been consistently demonstrated to be increased in 
patients with fibromyalgia. Bearing in mind that IL-8 promotes sympathetic pain, it may 
play an important role in the occurrence of pain in fibromyalgia. If validated in further 
studies, the IL-8 expression pattern might help in the diagnosis of fibromyalgia and in the 
appropriate treatment approach. 
Table 2 summarises the main findings for pro- and anti- inflammatory cytokines in 
fibromyalgia patients.  
 
Reference n° of subjects Samples Cytokines  
Findings in 
patients 
Wallace et al., 
2001  
56 
fibromyalgia 
36 controls 
serum IL-1ǃ, IL-2, IL-10, 
serum IL-2 receptor 
(sIL-2R), IFN-Ǆ, 
TNF-ǂ, IL-8, IL-6, 
IL-1Ra 
↑ IL-8, IL-1Ra 
Gür et al.,  
2002 
81 
fibromyalgia 
32 controls 
serum IL-I, sIL-2R, IL-6, 
IL-8 
↑ IL-8, sIL-2R 
Amel Kashipaz 
et al.,  
2003 
22 chronic 
fatigue 
syndrome / 
fibromyalgia 
19 controls 
cells TNF-ǂ, IL-1ǂ, IL-6, 
IL-10 
no differences 
Uçeyler et al., 
2006 
40 chronic 
fatigue 
syndrome (26 
fibromyalgia) 
40 controls 
mRNA  
from blood 
IL-2, IL-4, IL-8, IL-
10, TNF-ǂ, TGF-ǃ1 
↓ IL-4, IL-10 
Bazzichi et al., 
2007 
80 
fibromyalgia 
45 controls 
plasma IL-1, IL-6, IL-8, IL-
10, TNF-ǂ,  
↑ IL-8, IL-10, 
TNF-ǂ 
Wang et al., 
2008 
20 
fibromyalgia 
80 controls 
serum IL-4, IL-6, IL-8, IL-
10, TNF-ǂ, 
↑ IL-8, TNF-ǂ 
Wang et al., 
2009 
20 
fibromyalgia 
80 controls 
serum IL-8 six months 
after therapy, 
IL-8 was still 
significantly 
higher  
Kim et al., 2010 27 
fibromyalgia 
29 controls 
serum IL-1ǃ, IL-6, IL-8 ↑ IL-8 
Table 2. Cytokines in Fibromyalgia. 
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4. Proteomic markers 
In the last few years, it has become widely recognized that the genome represents only the 
first layer of complexity. Biological functions rely on a dynamic population of proteins, and 
the characterisation of the proteins can reveal posttranslational modifications (e.g., 
phosphorylation, glycosylation, and methylation), and give insight into protein-protein 
interactions and functions. For these reasons, there is an increasing interest in the field of 
proteomics wich is the identification of proteins contained in biological samples such as 
body fluids and tissue extracts. 
In 2005 Baraniuk and collaborators analyzed the cerebral spinal fluid of patients with 
chronic fatigue syndrome by quadrupole-time-of flight mass spectrometry, compared 
chronic fatigue syndrome with Persian Gulf War Illness and fibromyalgia, and concluded 
that the three proteomes overlapped (Baraniuk et al., 2005). Recently, we carried out a study 
on human whole saliva of patients affected by fibromyalgia. The aim was to identify the 
protein content of whole saliva and to determine the quantitative or qualitative differences 
between fibromyalgia patients and healthy subjects. We expected to find multiple 
biomarkers rather than a single one because a panel of biomarkers may correlate more 
reliably with fibromyalgia than a single protein (Bazzichi et al., 2009).  
In this work we used two-dimensional electrophoresis (2-DE) to obtain the whole saliva 
protein map of fibromyalgia patients. Figure 1 shows the typical protein pattern obtained 
from a healthy control subject (figure 1 A) and a fibromyalgia patient (figure 1 B).  
Matrix-assisted laser desorption ionization time-of-flight/ time-of-flight  mass spectrometry 
(MALDI-TOF/TOF MS) was used to identify proteins that we found differentially expressed 
from two analysed groups. In table 3, we report the most interesting proteins which 
emerged from the data analysis. 
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Fig. 1. Representative 2-DE gel map of salivary proteins. Control (A) and a fibromyalgia 
patient (B).  
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Spot 
n° 
Accession 
number
Protein name 
MW 
KDa
pI score 
coverage 
(%)
p-value 
253 P37837 transaldolase 38 6.3 181 42 <0.0001 
326 P18669 
phosphoglycerate 
mutase 1 
29 6.7 501 44 0.0011 
405 P62937 cyclophilin A 18 7.7 242 40 0.05 
407 P62937 cyclophilin A 18 7.7 450 58 0.0157 
452 P05109 calgranulin A 11 6.5 313 47 0.0036 
455 P05109 calgranulin A 11 6.5 187 37 0.0002 
474 P80511 calgranulin C 11 5.8 68 7 0.001 
Table 3. Protein identification of differentially expressed proteins in whole saliva of 
fibromyalgia patients by MS/MS 
Figure 2 shows the enlarged images of these proteins, histograms show the percentage 
volumes of the proteins and each bar represents the mean±SD of the mean of each spot. 
Significant differences from control whole saliva are based on Mann-Whitney test; (*p<0.05, 
**p<0.01, ***p<0.001). 
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Fig. 2. Enlarged images of the 2-DE gels highlighting some differentially expressed proteins 
for two representative gels. White: controls, Black: fibromyalgia. 
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Cyclophilin A resulted over-expressed in fibromyalgia patients in comparison with healthy 
subjects. Cyclophilin A  is a ubiquitously distributed protein belonging to the immunophilin 
family that can be secreted by cells in response to inflammatory stimuli (Arora et al., 2005). 
Secreted Cyclophilin A is a potent chemo attractant for monocytes, neutrophils, eosinophils 
and T cells in vitro. Satoh K and co-workers showed that Cyclophilin A is secreted from 
smooth muscle cells and macrophages also in response to oxidative stress (Satoh et al., 
2008). 
Other proteins found to be over expressed in fibromyalgia were calgranulins, belonging to 
the S100 multigene family implicated in a variety of intracellular activities such as cell 
proliferation and differentiation, cytoskeletal interactions, rearrangement and structural 
organization of membranes, intracellular Ca2+ homeostasis, cell migration, inflammation, 
and protection from oxidative cell damage (Yang et al., 2001). These proteins have already 
been found in autoinflammatory rheumatic diseases such as Sjögren Syndrome, 
Scleroderma, and Rheumatoid Arthritis (De Seny et al., 2008; Giusti et al., 2007a, 2007b, 
2010). Considering that fibromyalgia is defined as a non-inflammatory disease, we 
suggested that the over-expression of calgranulins might be related to a sub-inflammatory 
process, as suggested by the cytokine alterations. 
The main finding of our work was the significant over-expression of transaldolase and 
phosphoglycerate mutase 1 in fibromyalgia patients with respect to controls. The reliability 
of these potential biomarkers was assessed by receiver operating characteristic curves 
(figure 3). The sensitivity and the specificity of the transaldolase and phosphoglycerate 
mutase 1  were 77.3 and 84.6% and 95.5 and 50%, respectively. 
 
 
Fig. 3. ROC curve of transaldolase and phosphoglycerate mutase 1. 
Furthermore, we validated the results by western blot analysis (figure 4). The statistical 
analysis of the optical density of specific detected bands confirmed the significant up-
regulation of two enzymes in fibromyalgia patients with respect to controls. 
Transaldolase is an enzyme of the non-oxidative phase of the pentose phosphate pathway, 
which is involved in the generation of reduced nicotinamide adenine dinucleotide 
phosphate (NADPH). There is a lot of evidence have shown that oxidative stress and nitric 
oxide may play an important role in fibromyalgia pathophysiology (Ozgocmen et al., 2006).  
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The overexpression of transaldolase might be justified by the NADPH production, which 
could be involved in limiting oxidative damage to tissues. Moreover, transaldolase links the 
pentose phosphate pathway to glycolysis. From this point of view, it is interesting to note 
that phosphoglycerate mutase 1, an enzyme involved in glycolysis, was differently 
expressed in fibromyalgia patients.  
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Fig. 4. Western Blot analysis of transaldolase and phosphoglycerate mutase 1 in whole saliva 
samples from healthy subjects and fibromyalgia patients. Densitometry of the blots is 
shown. Values that are significantly different (p<0.05) as determined by the Mann-Whitney 
test, are indicated. 
In conclusion, our study has attested the potential usefulness of the proteomic 
characterization of human whole saliva in distinguishing fibromyalgia from healthy 
subjects. Moreover, the use of saliva may enable the easy characterization of non-invasively 
collected biological fluids, giving rise to a different approach in the diagnosis of 
fibromyalgia. The future focus of interest will be to validate the panel of biomarkers in 
different cohorts of pathological controls in order to identify biomarkers specific to 
fibromyalgia, and to exclude any interference of concomitant disorder (e.g. psychiatric 
comorbidities). 
However, this study allows us to focus on some of the peculiar pathogenic aspects of 
fibromyalgia, especially on the oxidative stress which contradistinguishes this condition.  
5. Conclusion 
The pathogenesis of fibromyalgia is not entirely understood and, at present, the diagnosis is 
only clinical. Up to now, no objective measures have been determined to be reliable 
biomarkers, and these measures can only reflect a predisposition to fibromyalgia. However, 
the different studies offer us insights into the pathophysiology of fibromyalgia. The 
proteomic analysis, rather than the gene expression profile, might have potential 
applications as a new tool for the diagnosis of fibromyalgia because proteins are the final 
effectors that mediate disease pathogenesis. Therefore, proteomic seems to represent a 
necessary element in the advancement of disease diagnosis and therapeutic targets.  
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Given the potential problems that can obscure any scientific enterprise, inconsistent results across studies are
bound to occur. How are we to decide what is true? Let's turn to philosophy for a reasonable answer. The
mathematician-philosopher Bertrand Russell approached a similar problem in his monograph The Problems of
Philosophy (Russell B, 1912). He addressed the following question: How do we know that anything is "real"? Is
the only reality subjective and simply in our minds, as Bishop Berkley challenged, or can we mostly believe the
objective reality? His pragmatic answer: All possibilities may be true, but when the preponderance of evidence
indicates that objective reality and knowledge are the most probable case, go with it. If the preponderance of
all evidence about the clinical description of fibromyalgia and it's pathogenic mechanisms and treatment
strategies indicate a highly probable interrelated hypothesis, go with it. The direction of the literature on the
whole trumps the less likely tangents. At the same time, remember Bertrand Russell and his pragmatic
answer, and keep an open mind.
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